LMWH Dosage in Chronic DVT
For chronic (extended) treatment of DVT beyond the initial acute phase, use dalteparin 150 U/kg subcutaneously once daily after an initial month at 200 U/kg once daily, or enoxaparin 1.5 mg/kg once daily (though this lacks specific long-term cancer trial data). 1
Initial Treatment Phase (First Month)
For the acute/initial treatment period of DVT:
- Dalteparin: 200 U/kg subcutaneously once daily 2
- Enoxaparin: 1 mg/kg subcutaneously twice daily OR 1.5 mg/kg once daily 2
- Tinzaparin: 175 U/kg once daily 3
The AT9 guidelines recommend full anticoagulant LMWH doses of enoxaparin 2 mg/kg once daily or dalteparin 200 U/kg once daily for once-daily dosing, though many clinicians use enoxaparin 1.5 mg/kg once daily based on clinical trial data. 2
Extended/Chronic Treatment Phase (After First Month)
The dosage should be reduced after the initial treatment period:
- Dalteparin: Reduce from 200 U/kg to 150 U/kg once daily after 1 month 1, 4, 1
- Enoxaparin: Continue at 1.5 mg/kg once daily OR 1 mg/kg twice daily 3, 1
- Alternative approach: Use 75-80% of the initial LMWH dose for extended therapy per ESMO recommendations 5, 4
Dalteparin has the strongest evidence for extended treatment in cancer-associated DVT, being the only LMWH FDA-approved for this indication and supported by the CLOT study showing superior efficacy versus warfarin (8.0% vs 15.8% recurrence rate). 1
Special Population Considerations
Severe Renal Insufficiency (CrCl <30 mL/min)
- Enoxaparin: Reduce to 1 mg/kg subcutaneously once daily (for treatment doses) 1
- Dalteparin: May be sufficiently cleared, but monitor peak anti-Xa levels (target 0.5-1.5 IU/mL, measured 4-6 hours post-dose after 3-4 doses) 1, 4, 1
- Enoxaparin carries 2-3 fold increased bleeding risk in severe renal impairment without dose adjustment 5, 1
Moderate Renal Impairment (CrCl 30-60 mL/min)
- Consider dose reduction for enoxaparin based on evidence of 31-44% reduced clearance 5, 4
- Exercise caution with LMWH accumulation 2
Obesity (BMI ≥40 kg/m²)
- Enoxaparin: Either standard 1 mg/kg every 12 hours OR reduced dose 0.8 mg/kg every 12 hours achieved similar anti-Xa levels (89.3% vs 76.9%) 1
Important Caveats
Duration of therapy: The term "chronic DVT" typically refers to extended anticoagulation beyond the acute phase. Most guidelines recommend:
- Minimum 3 months for provoked DVT 6
- At least 6 months for idiopathic DVT 7
- Indefinite therapy may be considered for recurrent unprovoked VTE 6
Monitoring: LMWH generally does not require routine monitoring except in special populations (severe renal impairment, extremes of weight, pregnancy) where anti-Xa levels may be checked. 5, 4, 8
Transition considerations: While DOACs are now preferred over vitamin K antagonists for most VTE patients due to lower bleeding risk and no monitoring requirements 6, LMWH remains the preferred agent for cancer-associated thrombosis and patients with contraindications to DOACs. 1